KPRX today
$1.35-$0.03 (-2.17%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minConsolidating
Daily trend turns up above $2.45
Key levels
Resistance$1.96
Resistance$1.77
Latest news & SEC filings
SEC FilingKiora Pharmaceuticals Inc filed a report on a major company event (Form 8-K)
DealKiora Pharmaceuticals gains rights to KIO-401, a late-stage pill for calpain inhibition
All KPRX news →About Kiora Pharmaceuticals
Kiora Pharmaceuticals develops medicines for diseases of the retina and is still in the testing stage, with no products approved for sale. Its main candidate, KIO-301, is a light-activated small molecule intended to restore vision in people with retinitis pigmentosa and other degenerative retinal conditions. Another candidate, KIO-104, is injected into the eye to treat retinal inflammation such as diabetic macular edema and posterior non-infectious uveitis, while KIO-101 is an eye drop version for ocular inflammation tied to autoimmune disease. The company runs trials in the United States and Australia and works with partners holding rights in various regions worldwide.
Based on the company's 10-K filed Mar 25, 2026.
Nasdaq · Healthcare
KIORA PHARMACEUTICALS INC (KPRX)
What Is the Price Target for KPRX?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is KPRX a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for KPRX.
Start Free Trial →Is KPRX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$6.77
12
Moat Score
NONE
3/9
Piotroski Score
-9.0
Altman Z-Score
What Is Smart Money Doing with KPRX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →KPRX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-403.45%
FCF Growth YoY
-217.8%
Revenue Trend
UNKNOWN
Dark Pool Trades for KPRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for KPRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:12:46 | $1.49 | 1,000 | $$1K | BUY |
| 15:24:49 | $1.43 | 1,543 | $$2K | SELL |
| 17:26:26 | $1.45 | 2,800 | $$4K | MIDPOINT |
| 18:39:56 | $1.49 | 2,900 | $$4K | SELL |
| 15:01:19 | $1.48 | 2,796 | $$4K | BUY |
5 dark pool trades shown · $$16K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for KIORA PHARMACEUTICALS INC (KPRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →KPRX — frequently asked questions
What is KPRX stock price today?
KIORA PHARMACEUTICALS INC (KPRX) is at $1.35, down 2.17% (-$0.03) at the Nov 11, 2026 close.
Why is KPRX stock moving today?
Latest KPRX news — Nov 12, 2026: Kiora Pharmaceuticals Inc filed a report on a major company event (Form 8-K) · Oct 30, 2026: Kiora Pharmaceuticals gains rights to KIO-401, a late-stage pill for calpain inhibition
Did KPRX beat earnings?
KPRX last reported on Aug 7, 2026: EPS -$0.34 vs -$0.47 expected — a beat of 27.7%.
Does KPRX pay a dividend?
KPRX does not currently pay a dividend.
What are KPRX support and resistance levels?
Resistance: $1.77, $1.96, $2.20.
What are insiders doing with KPRX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on KPRX?
Nov 12, 2026: Kiora Pharmaceuticals Inc filed a report on a major company event (Form 8-K) · Oct 30, 2026: Kiora Pharmaceuticals gains rights to KIO-401, a late-stage pill for calpain inhibition